| Date | Title | | | 12/19/08 | MannKind to Present at the 27th Annual J.P. Morgan Healthcare Conference| VALENCIA, Calif., Dec. 19 /PRNewswire-FirstCall/ -- MannKind Corporation
(Nasdaq: MNKD), focused on discovering, developing and commercializing
treatments for diabetes and cancer, announced today that it will present at
the 27th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2009
at 1:30 PM (PST) at the Westin St. Francis in San Francisco. In addition to
this presentation, the Company will host a breakfast meeting for investors and
analysts at 8:00 AM (PST) on Janua... |
|  | | 12/18/08 | MannKind Reports Top-Line Results from Two Pivotal Phase 3 Clinical Studies in Type 1 and Type 2 Diabetes| VALENCIA, Calif., Dec. 18 /PRNewswire-FirstCall/ -- MannKind Corporation
(Nasdaq: MNKD) today released preliminary top-line results from two pivotal
Phase 3 clinical studies of AFRESA(TM), the company's ultra rapid acting
insulin product (Studies 102 and 030). The protocols for these studies were
reviewed and prospectively approved by the FDA under its special protocol
assessment (SPA) procedure. As previously announced, both studies achieved
their primary endpoints.
Study 102 -... |
| | | 12/15/08 | MannKind Corporation to Review Positive Results From Final Two Pivotal Phase 3 Clinical Studies in Type 1 and Type 2 Diabetes| Live Broadcast on December 18, 2008 at 9 a.m. Eastern Time
VALENCIA, Calif., Dec. 15 /PRNewswire-FirstCall/ -- MannKind Corporation
(Nasdaq: MNKD) will host a live broadcast to review clinical results from its
final two Phase 3 studies of AFRESA(TM), the company's ultra rapid acting,
inhaled insulin product, at 9 a.m. Eastern Time on Thursday, December 18,
2008.
To participate in the live call by telephone, please dial (888) 677-5721
or (210) 839-8507. Those interested in vie... |
| | | 12/04/08 | MannKind Reports Positive Results from Final Two Pivotal Phase 3 Clinical Studies in Type 1 and Type 2 Diabetes| Pivotal efficacy and safety studies meet primary endpoints
VALENCIA, Calif., Dec. 4 /PRNewswire-FirstCall/ -- MannKind Corporation
(Nasdaq: MNKD) today announced that it has met the primary endpoints of its
final two pivotal Phase 3 studies of AFRESATM, the company's ultra rapid
acting, inhaled insulin product. The company expects to disclose more details
of the top-line data from these studies in patients with type 1 and type 2
diabetes (studies 030 and 102) by mid-December.
... |
| | | 11/25/08 | MannKind to Present at the Piper Jaffray 20th Annual Health Care Conference| VALENCIA, Calif., Nov. 25 /PRNewswire-FirstCall/ -- MannKind Corporation
(Nasdaq: MNKD), focused on discovering, developing and commercializing
treatments for diabetes and cancer, announced today that it will present at
the Piper Jaffray 20th Annual Health Care Conference on Tuesday, December 2,
2008 at 2:30 PM (EST) at the New York Palace Hotel in New York City.
Interested parties can access a link to the live web cast of the
presentation in the Investor Relations section of the... |
| | | 11/05/08 | MannKind Corporation Reports Third Quarter Financial Results| - Conference Call Today at 9:00 a.m. EST -
VALENCIA, Calif., Nov. 5 /PRNewswire-FirstCall/ -- MannKind Corporation
(Nasdaq: MNKD) today reported financial results for the third quarter ended
September 30, 2008.
For the third quarter of 2008, total operating expenses were $69.1
million, compared to $75.6 million for the third quarter of 2007, primarily
attributable to the $9.2 million reduction in research and development (R&D)
expenses which totaled $55.6 million... |
| | | 11/03/08 | MannKind to Present at the Rodman & Renshaw Annual Global Investment Conference| VALENCIA, Calif., Nov. 3 /PRNewswire-FirstCall/ -- MannKind Corporation
(Nasdaq: MNKD), focused on discovering, developing and commercializing
treatments for diabetes and cancer, announced today that it will present at
the Rodman & Renshaw Annual Global Investment Conference on Monday, November
10, 2008 at 9:55 AM (EST) at the New York Palace Hotel in New York City.
Interested parties can access a link to the live web cast of the
presentation in the Investor Relations section of th... |
| | | 10/29/08 | MannKind Corporation to Hold Third Quarter Financial Results Conference Call on November 5, 2008| VALENCIA, Calif., Oct. 29 /PRNewswire-FirstCall/ -- MannKind Corporation
(Nasdaq: MNKD) will release its 2008 third quarter financial results on
Wednesday, November 5, 2008 at 8:00 a.m. EST.
Management of the Company will host a conference call to discuss the third
quarter financial results, clinical progress and other Company developments at
9:00 a.m. EST on November 5, 2008. Presenting from the Company will be its
Chairman and Chief Executive Officer, Alfred Mann; President and C... |
| | | 09/17/08 | MannKind Unveils Proposed Trade Name at Dedication of Danbury Manufacturing Facility| DANBURY, Conn., Sept. 17 /PRNewswire-FirstCall/ -- MannKind Corporation
(Nasdaq: MNKD) today announced that it has proposed to the United States Food
and Drug Administration to use AFRESA as the trade name for its Technosphere
Insulin System.
AFRESA (pronounced uh-FRESS-uh) was unveiled today by Alfred Mann,
Chairman and Chief Executive Officer of MannKind, during a ceremony at the
company's Danbury, Conn., location that marked the completion and dedication
of a new facility for t... |
| | | 09/16/08 | MannKind and Pfizer Announce Collaboration for Certain Exubera Patients to Transition to MannKind's Inhaled Insulin Therapy| VALENCIA, Calif. & NEW YORK, Sep 16, 2008 (BUSINESS WIRE) -- MannKind Corporation (Nasdaq: MNKD) and Pfizer Inc (NYSE: PFE) announced
today that MannKind will transition certain Exubera patients with a
continuing need for inhaled insulin to MannKind's
inhaled insulin product, Technosphere(R)
Insulin. Technosphere Insulin is an investigational product that has
recently completed Phase 3 clinical trials.
In October 2007, Pfizer announced that it would stop ... |
| | | 09/16/08 | MannKind Reports Positive Data from a Phase 3 Clinical Study of Technosphere Insulin in Type 1 Diabetes| Study 009 meets its primary endpoint of non-inferiority to a rapid-acting
insulin analog
VALENCIA, Calif., Sept. 16 /PRNewswire-FirstCall/ -- MannKind Corporation
(Nasdaq: MNKD) today released preliminary top-line results from a Phase 3
clinical study of the Technosphere(R) Insulin System in patients with type 1
diabetes (Study 009). This study compared the safety and efficacy of prandial
inhalations of Technosphere Insulin (the TI group) versus prandi... |
| | | 09/15/08 | MannKind to Present at the UBS Global Life Sciences Conference|
VALENCIA, Calif., Sept. 15 /PRNewswire-FirstCall/ -- MannKind Corporation
(Nasdaq: MNKD), focused on discovering, developing and commercializing
treatments for diabetes and cancer, announced today that it will present at
the UBS Global Life Sciences Conference on Tuesday, September 23, 2008 at
10:00 AM (ET) at the Grand Hyatt in New York.
Interested parties can access a link to the live web cast of the
presentation in the Investor Relations section of the Company's website at
ht... |
| | | 09/11/08 | MannKind Corporation to Host Webcast Analyst Day September 16, 2008| Company To Review Data from First Pivotal Phase 3 Clinical Trial
VALENCIA, Calif., Sept. 11 /PRNewswire-FirstCall/ -- MannKind Corporation
(Nasdaq: MNKD) today announced that it will host an analyst day for the
investment community to review clinical results from Phase 3 and other
clinical trials of the company's Technosphere(R) Insulin System. The meeting
will take place on Tuesday, September 16, 2008 from 9 a.m. to 11 a.m. Eastern
Time in New York City. To access the live au... |
| | | 08/11/08 | MannKind Corporation Reports Second Quarter Financial Results| - Conference Call Today at 5:00 p.m. EDT -
VALENCIA, Calif., Aug. 11 /PRNewswire-FirstCall/ -- MannKind Corporation
(Nasdaq: MNKD) today reported financial results for the second quarter ended
June 30, 2008.
For the second quarter of 2008, total operating expenses were
$80.9 million, compared to $75.4 million for the second quarter of 2007. This
increase was primarily attributable to increased research and development
(R&D) expenses which totaled $67.6 million f... |
| | | 08/04/08 | MannKind Corporation to Hold Second Quarter Financial Results Conference Call on August 11, 2008| VALENCIA, Calif., Aug. 4 /PRNewswire-FirstCall/ -- MannKind Corporation
(Nasdaq: MNKD) will release its 2008 second quarter financial results on
Monday, August 11, 2008 at 4:00 p.m. EDT.
Management of the Company will host a conference call to discuss the
second quarter financial results, clinical progress and other Company
developments at 5:00 p.m. EDT on Monday, August 11, 2008. Presenting from the
Company will be its Chairman and Chief Executive Officer, Alfred Mann;
President ... |
| | | 06/16/08 | MannKind to Present at Upcoming Conferences| VALENCIA, Calif., June 16, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- MannKind Corporation
(Nasdaq: MNKD), focused on discovering, developing and commercializing
treatments for diabetes and cancer, announced today that it will present at
upcoming conferences.
18th Annual Wachovia Nantucket Equity Conference on Monday, June 23,
2008 at 11:45 AM (Eastern Time) at The White Elephant in Nantucket
Island, Massachusetts
2nd Annual Jefferies Healthcare Confere... |
| | | 05/07/08 | MannKind to Present at Upcoming Conferences| VALENCIA, Calif., May 7 /PRNewswire-FirstCall/ -- MannKind Corporation
(Nasdaq: MNKD), focused on discovering, developing and commercializing
treatments for diabetes and cancer, announced today that it will present at
upcoming conferences.
Bank of America Health Care Conference on Wednesday, May 14, 2008 at
8:40 AM (Pacific Time) at the Four Seasons Hotel, Las Vegas, Nevada
Baird's 2008 Growth Stock Conference on Thursday, May 15, 2008 at
8:55 AM (Central Time) at t... |
| | | 05/05/08 | MannKind Corporation Reports First Quarter Financial Results| - Conference Call Today at 5:00 p.m. EDT -
VALENCIA, Calif., May 5 /PRNewswire-FirstCall/ -- MannKind Corporation
(Nasdaq: MNKD) today reported financial results for the first quarter ended
March 31, 2008.
For the first quarter of 2008, total operating expenses were
$74.1 million, compared to $77.3 million for the first quarter of 2007.
Research and development (R&D) expenses decreased by $5.3 million to
$58.4 million for the first quarter of 2008 compared to the... |
| | | 05/05/08 | The Leukemia & Lymphoma Society and MannKind Corporation Announce Collaborative Research Agreement| New Partnership under LLS's Therapy Acceleration Program to Advance
Development of a Novel Targeted Therapy for T-Cell Leukemia and Lymphoma
WHITE PLAINS, N.Y. and VALENCIA, Calif., May 5 /PRNewswire-FirstCall/ --
The Leukemia & Lymphoma Society (LLS) and MannKind Corporation, (MNKD), today
jointly announced the execution of a collaborative research arrangement funded
through LLS's Therapy Acceleration Program (TAP).
TAP is an innovative program intended to advance therapie... |
| | | 04/28/08 | MannKind to Present at the Morgan Stanley Healthcare Conference| VALENCIA, Calif., April 28 /PRNewswire-FirstCall/ -- MannKind Corporation
(Nasdaq: MNKD), focused on discovering, developing and commercializing
treatments for diabetes and cancer, announced today that it will present at
the Morgan Stanley Healthcare Conference on Wednesday, April 30, 2008 at 8:30
AM ET at The Ritz-Carlton, Key Biscayne, Florida.
Interested parties can access a link to the live web cast of the
presentation in the Investor Relations section of the Company's website ... |
| | | 04/28/08 | MannKind Corporation to Hold First Quarter Financial Results Conference Call on May 5, 2008| VALENCIA, Calif., April 28 /PRNewswire-FirstCall/ -- MannKind Corporation
(Nasdaq: MNKD) will release its 2008 first quarter financial results on
Monday, May 5, 2008 at 4:00 p.m. EDT.
Management of the Company will host a conference call to discuss the first
quarter financial results, clinical progress and other Company developments at
5:00 p.m. EDT on Monday, May 5, 2008. Presenting from the Company will be its
Chairman and Chief Executive Officer, Alfred Mann; President and Chief... |
| | | 04/16/08 | Matthew J. Pfeffer Joins MannKind as Corporate Vice President and Chief Financial Officer| VALENCIA, Calif., April 16 /PRNewswire-FirstCall/ -- MannKind Corporation
(Nasdaq: MNKD) today announced that Matthew J. Pfeffer will join the company
as Corporate Vice President and Chief Financial Officer, effective April 21,
2008. Mr. Pfeffer will report to Hakan Edstrom, President and Chief Operating
Officer, and will serve on MannKind's executive leadership team. Mr.
Pfeffer's appointment follows the previously announced retirement of Dick
Anderson, who has now transitioned to th... |
| | | 04/10/08 | MannKind Addresses Pfizer's Announcement Regarding Exubera| VALENCIA, Calif., April 10 /PRNewswire-FirstCall/ -- MannKind Corporation
(Nasdaq: MNKD) released the following statement in response to the
announcement by Pfizer Inc. that over the course of Exubera's clinical trial
program, 6 of the 4,740 patients treated with Exubera developed lung cancer,
although Pfizer concluded that there were too few cases to determine whether
this observation was related to Exubera. According to Pfizer's "Dear Doctor"
letter, Exubera remains a safe and effec... |
| | | 03/13/08 | MannKind to Present at the Cowen and Company Healthcare Conference| VALENCIA, Calif., March 13 /PRNewswire-FirstCall/ -- MannKind Corporation
(Nasdaq: MNKD), focused on discovering, developing and commercializing
treatments for diabetes and cancer, announced today that it will present at
the Cowen and Company Healthcare Conference on March 17, 2008 at 3:15 PM ET at
the Marriott Copley Place Hotel in Boston, MA.
Interested parties can access a link to the live web cast of the
presentation in the Investor Relations section of the Company's website at... |
| | | 03/10/08 | MannKind Corporation Response to Recent Market Events| VALENCIA, Calif., March 10 /PRNewswire-FirstCall/ -- MannKind Corporation
(Nasdaq: MNKD) today issued the following statement in response to recent
market events:
MannKind is absolutely committed to the continued development of its lead
development product, Technosphere(R) Insulin. We use our small,
patient-friendly Medtone(R) inhaler to deliver Technosphere(R) Insulin to
patients with diabetes in a way that much more closely matches the pattern of
insulin secretion seen in people... |
| | | 03/04/08 | MannKind Corporation Reports Fourth Quarter and Full Year 2007 Financial Results| - Conference Call to Begin Today at 9:00 a.m. ET -
VALENCIA, Calif., March 4 /PRNewswire-FirstCall/ -- MannKind Corporation
(Nasdaq: MNKD) today reported financial results for the fourth quarter and
year ended December 31, 2007.
For the fourth quarter of 2007, total operating expenses were
$79.1 million, compared to $71.8 million for the fourth quarter of 2006.
Research and development (R&D) expenses increased by $7.0 million to
$66.8 million for the fourth quarter o... |
| | | 02/28/08 | MannKind Corporation to Hold Fourth Quarter Financial Results Conference Call on March 4, 2008| VALENCIA, Calif., Feb 28, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- MannKind Corporation
(Nasdaq: MNKD) will release its 2007 fourth quarter financial results on
Tuesday, March 4, 2008 at 7:00 a.m. ET.
Management of the Company will host a conference call to discuss the
fourth quarter financial results, clinical progress and other Company
developments at 9:00 a.m. ET on Tuesday, March 4, 2008. Presenting from the
Company will be its Chairman and Chief Executive Officer, Alfred... |
| | | 02/01/08 | MannKind to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference| VALENCIA, Calif., Feb. 1 /PRNewswire-FirstCall/ -- MannKind Corporation
(Nasdaq: MNKD), focused on discovering, developing and commercializing
treatments for diabetes and cancer, announced today that it will present at
the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device
Conference on February 6, 2008 at 1:40 PM ET at the Grand Hyatt Hotel in New
York, NY.
Interested parties can access a link to the live web cast of the
presentation in the Investor Relatio... |
| | | 01/25/08 | MannKind to Present at the Wachovia 2008 Healthcare Conference| VALENCIA, Calif., Jan. 25 /PRNewswire-FirstCall/ -- MannKind Corporation
(Nasdaq: MNKD), focused on discovering, developing and commercializing
treatments for diabetes and cancer, announced today that it will present at
the Wachovia Healthcare Conference on January 30, 2008 at 2:00 PM ET at the
Langham Hotel in Boston, MA.
Interested parties can access a link to the live web cast of the
presentation in the Investor Relations section of the Company's website at
http://www.mannkindc... |
| | | 01/07/08 | John R. Riesenberger Joins MannKind as Corporate Vice President and Chief Commercialization Officer| VALENCIA, Calif., Jan 07, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- MannKind Corporation
(Nasdaq: MNKD), today announced that John Riesenberger has joined the company
as Corporate Vice President and Chief Commercialization Officer. Mr.
Riesenberger will report to Hakan Edstrom, President and Chief Operating
Officer, and serve on MannKind's executive leadership team.
At MannKind, Mr. Riesenberger will lead the functional areas of marketing,
sales, alliance management and busine... |
| | | 01/02/08 | MannKind to Present at the JP Morgan Healthcare Conference| VALENCIA, Calif., Jan. 2 /PRNewswire-FirstCall/ -- MannKind Corporation
(Nasdaq: MNKD), focused on discovering, developing and commercializing
treatments for diabetes and cancer, announced today that it will present at
the JP Morgan Healthcare Conference on January 8, 2008 at 8:00 a.m. Pacific
Time at the Westin St. Francis Hotel in San Francisco, CA.
Interested parties can access a link to the live web cast of the
presentation in the Investor Relations section of the Company's web... |
| |
|
Print | 
E-mail Page | 
RSS Feeds | 
E-mail Alerts | 
IR Contacts | 
Tear Sheet
